Literature DB >> 31627779

Implementation of Xpert® MTB/RIF: real challenges, real promise.

D W Dowdy1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31627779      PMCID： PMC7860149          DOI： 10.5588/ijtld.19.0120

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  4 in total

1.  Expand the RRDR hotspot to improve GeneXpert results.

Authors:  B Mishra; P R Mohapatra
Journal:  Int J Tuberc Lung Dis       Date:  2019-09-01       Impact factor: 2.373

2.  Peripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswana.

Authors:  Tefera Agizew; Rosanna Boyd; Ndwapi Ndwapi; Andrew Auld; Joyce Basotli; Sambayawo Nyirenda; Zegabriel Tedla; Anikie Mathoma; Unami Mathebula; Chawangwa Lesedi; Sherri Pals; Anand Date; Heather Alexander; Thomas Kuebrich; Alyssa Finlay
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

3.  Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.

Authors:  Denise Evans; Tembeka Sineke; Kathryn Schnippel; Rebecca Berhanu; Caroline Govathson; Andrew Black; Lawrence Long; Sydney Rosen
Journal:  BMC Health Serv Res       Date:  2018-12-17       Impact factor: 2.655

4.  Ensuring that Xpert® MTB/RIF is used to its maximum potential.

Authors:  A D Harries; C Timire; K C Takarinda; C Sandy
Journal:  Int J Tuberc Lung Dis       Date:  2019-09-01       Impact factor: 2.373
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.